Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR for Agitation in Acute Schizophrenia
NCT00954122Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of quetiapine in schizophrenia, sponsored by AstraZeneca. Primary endpoint: Positive and Negative Syndrome Scale Excited Component at Day 21. Started Sep 2009; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00954122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00954122.